Ethypharm has announced the appointment of Foucauld Ruyant as its new Chief Financial Officer (CFO), effective from September 25, 2023. Ruyant will be based in Saint Cloud and will report directly to Denis Delval (CEO), becoming a member of the Executive Committee (ExCom).
Ruyant brings over two decades of financial management experience working in an international environment with a focus on industrial. He began his career in auditing at KPMG, one of the world’s leading professional services firms, before moving on to Suntory Beverage and Food. At Suntory, he held senior positions in management, accounting, treasury, and tax in France and Europe, covering all financial activities for 15 years.
In 2021, Ruyant took on the role of CFO at the Cenexi group, an outsourced pharmaceutical manufacturing company, first owned by an investment fund and then by the international Indian group Gland Pharma. His tenure at Cenexi was marked by successful leadership of multicultural teams, and driving profitable growth and shareholder value.
Ruyant’s educational background includes studying accounting and finance in Paris and completing a Master’s degree at Glasgow University. His solid experience in finance and his proven track record of scaling companies in complex, regulated organizations make him a valuable addition to the Ethypharm team.
Ethypharm is confident that Ruyant’s extensive experience and expertise will be instrumental in driving the company’s financial strategy and supporting its mission. The company welcomes Ruyant and wishes him every success in his new role.
